A Cohort of Molecular Characteristics and Prognosis of Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study aims to establish a colorectal cancer cohort, collect clinicopathological information, collect biological samples for multi-omics testing, and perform relevant analysis, to predict the prognosis of colorectal cancer, guide the diagnosis and treatment of colorectal cancer and the formulation of health policies.
Condition or disease
Procedure: colorectal cancer surgery
In this study, the investigators will establish a database to collect clinical pathological information, based on the medical data system of participating medical centers. The investigators will also collect corresponding tumor specimens and perform multiple omics tests such as genome, transcriptome, and proteome. The investigators will aggregate these data into a special database, and use appropriate methods to conduct big data analysis, to predict prognosis, guide diagnosis and treatment, and assist in formulating health policies.
Disease-free survival time [ Time Frame: 2 yeas after surgery ]
For patients received radical resection of colorectal cancer, disease-free survival time is defined as time from the surgery to any recurrence of disease or death, recorded in months.
Secondary Outcome Measures :
Overall survival time [ Time Frame: 2 yeas after surgery ]
Overall survival time is defined as time from the surgery to death, recorded in months.
Pathological TNM stage [ Time Frame: 1 month after surgery ]
The pathological TNM stage included the pathological T stage, pathological N stage and M stage. The pathological T and N stage is decided according to the removed specimen of the primary tumor by the pathologist after surgery. The M stage is decided according to the imaging tests as CT, MRI and PET-CT.
Biospecimen Retention: Samples With DNA
The specimens include primary tumor tissue, adjacent tissues, normal mucosa tissue, and peripheral venous blood. Tissue samples will be used for multiple omics tests, including genome, transcriptome, proteome, etc. Blood samples are used for tumor markers, immunology and other tests.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
All patients pathologically diagnosed as colorectal cancer, and receiving any surgery of primary tumor, including palliative resection, simple enterostomy and exploratory surgery
Pathologically diagnosed as colorectal cancer
Receiving any surgery of primary tumor, including palliative resection, simple enterostomy and exploratory surgery
The patient refused to join the study
The patient refused to collect the biological sample